Esophageal squamous cell carcinoma (ESCC) is a common and aggressive form of cancer, with a high risk of postoperative recurrence. Accurate prediction of recurrence is essential for optimizing follow-up care and tailoring treatment strategies to improve patient outcomes.
Esophageal squamous cell carcinoma (ESCC) is a common and aggressive form of cancer, with a high risk of postoperative recurrence. Accurate prediction of recurrence is essential for optimizing follow-up care and tailoring treatment strategies to improve patient outcomes. Traditional models for predicting overall survival in ESCC often lack focus on postoperative recurrence, which is a critical factor affecting long-term survival.
A recent study developed and validated a machine learning model based on support vector machines (SVM) to predict postoperative recurrence in ESCC patients. The study analyzed clinical data from 310 patients who underwent surgery, using preoperative, intraoperative, and postoperative variables such as tumor markers, inflammatory markers, TNM stage, and complications. Key risk factors identified included age, ECOG performance status, neutrophil-to-lymphocyte ratio (NLR), C-reactive protein-to-prealbumin ratio (CPR), CY211, TNM stage, and postoperative complications.
The best-performing model, SVM6+8, achieved high sensitivity (94% in the test cohort) and strong predictive accuracy. A nomogram based on the SVM6+TNM model was developed to estimate 1-, 3-, and 5-year disease-free survival (DFS). Kaplan-Meier survival analysis showed significantly improved DFS in low-risk patients.
This machine learning approach provides clinicians with a reliable tool to stratify patients into high- and low-risk groups, enabling personalized follow-up schedules and adjuvant therapy planning. While the study demonstrated robust internal validation, external validation is needed to confirm its generalizability. Nonetheless, the integration of machine learning with clinical data represents a significant advancement in ESCC management.
Introduction: Artificial intelligence is rapidly transforming healthcare through drug discovery, clinical decision support, remote monitoring, and administrative automation. While AI is widely expected to reduce healthcare costs, this perspective argues that current payment models and...
Introduction: Large frontier AI models such as GPT-5 and Gemini have achieved impressive results across numerous healthcare benchmarks. However, high benchmark scores alone may not reflect real-world clinical reliability. This study systematically evaluated the robustness...
Introduction: Artificial intelligence is rapidly transforming medicine, but its influence extends far beyond healthcare. This JAMA AI Conversations article explores how AI ethics has become a global societal issue, engaging technology leaders, policymakers, healthcare professionals,...
Introduction: Artificial intelligence is rapidly transforming oncology, evolving from image interpretation and pathology analysis to supporting complex clinical decision-making. This perspective argues that AI should enhance the capabilities of oncologists rather than replace their expertise....
Introduction Clinical trial endpoints have traditionally relied on expert human interpretation, particularly for pathology-based outcomes. However, variability between observers, cost, and time remain important limitations. This NEJM AI perspective discusses how artificial intelligence is beginning...
Introduction: As artificial intelligence becomes increasingly integrated into clinical practice, an important question arises: should AI assistants be regulated as medical devices or viewed as evidence-based clinical methodologies? This NEJM AI perspective proposes a new...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.